Literature DB >> 22985810

Age and comorbidity considerations related to radiotherapy and chemotherapy administration.

George Rodrigues1, Michael Sanatani.   

Abstract

Oncological treatment decision-making is a highly complex enterprise integrating multiple patient, tumor, treatment, and professional factors with the available medical evidence. This management complexity can be exacerbated by the interplay of patient age and comorbid non-cancer conditions that can affect patient quality of life, treatment tolerance, and survival outcomes. Given the expected increase in median age (and associated comorbidity burden) of Western populations over the next few decades, the use of evidence-based therapies that appropriately balance treatment intensity and tolerability to achieve the desired goal of treatment (radical, adjuvant, salvage, or palliative) will be increasingly important to health care systems, providers, and patients. In this review, we highlight the evidence related to age and comorbidity, as it relates to radiotherapy and chemotherapy decision making. We will address evidence as it relates to age and comorbidity considerations separately and also the interplay between the factors. Clinical considerations to adapt radiation and/or chemotherapy treatment to deal with comorbidity challenges will be discussed. Knowledge gaps, future research, and clinical recommendation in this increasingly important field are highlighted as well.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22985810     DOI: 10.1016/j.semradonc.2012.05.004

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  7 in total

1.  Impact of comorbidity on survival after palliative radiotherapy.

Authors:  Carsten Nieder; Kirsten Engljähringer; Kent Angelo
Journal:  Strahlenther Onkol       Date:  2014-07-15       Impact factor: 3.621

2.  The effect of comorbidities on outcomes in colorectal cancer survivors: a population-based cohort study.

Authors:  Colleen A Cuthbert; Brenda R Hemmelgarn; Yuan Xu; Winson Y Cheung
Journal:  J Cancer Surviv       Date:  2018-09-06       Impact factor: 4.442

3.  How Should Palliative Thoracic Radiotherapy Be Fractionated for Octogenarians with Lung Cancer?

Authors:  Carsten Nieder; Rosalba Yobuta; Bård Mannsåker; Astrid Dalhaug
Journal:  In Vivo       Date:  2018 Mar-Apr       Impact factor: 2.155

4.  Feasibility of radiotherapy in nonagenarian patients: a retrospective study.

Authors:  L Kocik; H Geinitz; C Track; M Geier; C Nieder
Journal:  Strahlenther Onkol       Date:  2018-08-30       Impact factor: 3.621

Review 5.  The pharmacological bases of the antiangiogenic activity of paclitaxel.

Authors:  Guido Bocci; Antonello Di Paolo; Romano Danesi
Journal:  Angiogenesis       Date:  2013-02-07       Impact factor: 9.596

6.  The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects.

Authors:  Michaela Medová; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Cancers (Basel)       Date:  2013-12-19       Impact factor: 6.639

7.  Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians).

Authors:  Carsten Nieder; Thomas A Kämpe
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2017-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.